Heartseed Inc. (219A.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 11Sep 16Sep 24Sep 29Oct 2Oct 7Oct 13Oct 16

Key dataOct 16, 2026

OpenJPY 2,690.00

From 52W high−4.57%

Volume308200.00

Market capJPY 60.24B

P/E (TTM)369.6x

P/S (TTM)19.9x

Div yield—

Key dataOct 16, 2026

Open

JPY 2,690.00

From 52W high

−4.57%

Volume

308200.00

Market cap

JPY 60.24B

ValuationView details →

P/E (Fwd)

396.8x

EV/EBITDA

193.4x

P/E (TTM)

369.6x

RSI (14)

59.9

MomentumView details →

1D Return

−2.41%

YTD Return

+49.39%

ValuationView details →

P/E (Fwd)

396.8x

P/E (TTM)

369.6x

EV/EBITDA

193.4x

EV/Sales

17.8x

P/S (TTM)

19.9x

P/B (TTM)

9.0x

ProfitabilityView details →

Gross Margin

100.02%

Net Margin

6.28%

EBITDA Margin

10.74%

ROE (TTM)

2.64%

ROA (TTM)

2.48%

Asset Turnover

0.39x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+246.62%

EPS CAGR 3Y

+117.07%

EBITDA YoY

—

MomentumView details →

1D Return

−2.41%

YTD Return

+49.39%

1Y Return

+47.27%

RSI (14)

59.9

vs 50D SMA

+14.98%

vs 200D SMA

+40.12%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

22.30x

Quick Ratio

22.30x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

3.01B

Net Income (TTM)

610.00M

Op. CF (TTM)

—

Next earningsNov 13, 2026 →

Latest newsMore news →

Heartseed obtained a regenerative medicine product manufacturing and marketing license from the Tokyo Metropolitan Government.19d ago

Heartseed announced clinical trial results for its iPS cell-derived cardiomyocyte product for heart failure, confirming efficacy and safety, and aims to file for approval within the year.46d ago

Similar companies

KYORIN Pharmaceutical Co.,Ltd.4569.T ASKA Pharmaceutical Holdings Co.,Ltd.4886.T JCR Pharmaceuticals Co.,Ltd.4552.T TAUNS Laboratories,Inc.197A.T SanBio Company Limited4592.T Cuorips Inc.4894.T Find similar companies →

Latest newsMore news →

Heartseed obtained a regenerative medicine product manufacturing and marketing license from the Tokyo Metropolitan Government.19d ago Heartseed announced clinical trial results for its iPS cell-derived cardiomyocyte product for heart failure, confirming efficacy and safety, and aims to file for approval within the year.46d ago Heartseed applied to the Tokyo Metropolitan Government for a manufacturing and sales license for regenerative medicine products.60d ago